RxDoctor Payments Data

Joelle Innocent Simon, DO

Family Medicine · Starke, FLNPI 1205970134

Payments from drug & device makers

$385in general payments, 2019–2025

Across 19 payments — averaging $20.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$84
  • Mylan Specialty L.p.$75
  • AstraZeneca$50
  • Bridgebio Pharma, Inc.$30
  • Bard Peripheral Vascular, Inc.$26
  • Astellas Pharma US Inc$23
  • plus $97 from 6 others

What the payments were for

  • Food & beverage$385100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$385 in reported general payments places this provider in the 45th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$426,569
Medicare patients
751
Services billed
5,191

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban797$293,938
JanuviaSitagliptin Phosphate263$134,300
OzempicSemaglutide132$134,106
JardianceEmpagliflozin227$112,730
TrulicityDulaglutide75$72,837
GemtesaVibegron263$67,999
Trelegy ElliptaFluticasone/Umeclidin/Vilanter93$63,927
NuedextaDextromethorphan Hbr/Quinidine81$57,691
XareltoRivaroxaban123$45,862
FarxigaDapagliflozin Propanediol124$45,203
Dupixent SyringeDupilumab12$43,801
MyrbetriqMirabegron128$42,976
MounjaroTirzepatide42$42,524
EntrestoSacubitril/Valsartan78$36,374
LinzessLinaclotide52$34,652

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$18$134,106132 claims
Lilly USA, LLCTrulicity, Mounjaro$84$115,361117 claims
Sumitomo Pharma America, Inc.Gemtesa$21$67,999263 claims
AstraZenecaFarxiga$50$45,203124 claims
Astellas Pharma US IncMyrbetriq$23$42,976128 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Starke

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →